FDG PET measurement of the proliferative potential of non-small cell lung cancer

Journal of Nuclear Medicine

Volumn 41, Issue 1, 2000, Pages 85-92

  Higashi, Kotaro ^a   Ueda, Yoshimichi ^b   Yagishita, Masami ^b   Arisaka, Yukiko ^b   Sakurai, Aya ^b   Oguchi, Manabu ^b   Seki, Hiroyasu ^b   Nambu, Yoshihiro ^b   Tonami, Hisao ^b   Yamamoto, Itaru ^b  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

Cell proliferation; Cellular density; FDG; Lung cancer; PET

Indexed keywords

CYCLINE; FLUORODEOXYGLUCOSE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL DENSITY; CELL PROLIFERATION; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROLIFERATING CELL NUCLEAR ANTIGEN; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033978780     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Mathews MB, Bernstein RM, Franza BR, et al. Identity of the proliferating cell nuclear antigen and cycline. Nature. 1984;309:374-376.
2. Bravo R, Frank R, Blundell PA, et al. Cycline/PCNA is the auxiliary protein of DNA polymerase delta. Nature. 1984;326:515-517.
3. Kitamoto M, Nakanishi T, Kira S, et al. The assessment of proliferating cell nuclear antigen immunohistochemical staining in small hepatocellular carcinoma and its relationship to histologic characteristics and prognosis. Cancer. 1993;72: 1859-1865.
4. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med. 1990;31: 1927-1933.
5. Wahl RL. Positron emission tomography: applications in oncology. In: Murray IPC, Ell PJ, ed. Nuclear Medicine in Clinical Diagnosis and Treatment. Vol 2. New York, NY: Churchill Livingstone; 1994:801-820.
6. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med. 1996;37:943-948.
7. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med. 1998;39:1016-1020.
8. Kim B-T, Kim Y, Lee KS, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR. 1998;170:935-939.
9. Jang H-J, Lee KS, Kwon OJ, et al. Bronchioloalveolar carcinoma: focal area of ground-glass attenuation at thin-section CT as an early sign. Radiology. 1996;199: 485-488.
10. Heikkila L, Mattila P, Harjiula A, et al. Tumor growth rate and its relationship to prognosis in bronchiolo-alveolar and pulmonary adenocarcinoma. Ann Chir Gynaecol. 1985;74:210-214.
11. 18F-fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:1323-1329.
12. Minn H, Joensuu H, Ahonen A. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo - comparison with DNA flow cytometry in head and neck tumors. Cancer. 1988;61:1776-1781.
13. Duhaylongsod FG, Lowe VJ, Patz EF, et al. Lung tumor growth correlations with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg. 1995;60:1348-1362.
14. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med. 1992;33:325-329.
15. Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. J Nucl Med. 1998;39:1302-1305.
16. Kubota K, Matsuzawa T, Ito M, et al. Lung tumor imaging by positron emission tomography using C-11-L-methionine. J Nucl Med. 1985;26:37-42.
17. Higashi T, Tamaki N, Torizuka T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med. 1998;39:1727-1735.
18. Kawai T, Suzuki M, Kono S, et al. Proliferating cell nuclear antigen and Ki-67 in lung cancer. Cancer. 1994;74:2468-2475.
19. Morimura T, Kitz K, Budka H. In situ analysis of cell kinetics in brain tumors. Acta Neuropathol. 1989;77:276-282.
20. Herholz K, Pietrzyk U, Voges J, et al. Correlation of glucose consumption and tumor cell density in astrocytomas. J Neurosurg. 1993;79:853-858.
21. Kuwert T, Probst-Cousin S, Woesler B, et al. Iodine-123-methyl tyrosine in gliomas: correlation with cellular density and proliferative activity. J Nucl Med. 1997;38:1551-1555.
22. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34:414-119.
23. Ito K, Kato T, Tadokoro M, et al. Fluorine-18-fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: relation to tumor size and cellularity. Eur J Nucl Med. 1996;23:1372-1377.
24. Kato T, Fukatsu H, Ito K, et al. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: unsolved problem. Eur J Nucl Med. 1995;22:32-39.
25. 18FDG-PET in intracranial meningiomas versus grading, proliferation index, cellular density and cytogenetical analysis [in German]. Nuklearmedizin. 1994;33:144-149.
26. Hatanaka M. Transport of sugars in tumor cell membranes. Biochem Biophys Acta. 1974;355:77-104.
27. Flier JS, Mueckler MM, Usher P, et al. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492-1495.
28. Isselbacher KJ. Increased uptake of amino acids and 2-deoxy-D-glucose by virus-transformed cell in culture. Proc Natl Acad Sci USA. 1972;69:585-589.
29. Weber G. Enzymology of cancer cells. N Engl J Med. 1977;296:541-551.
30. Sweeney MJ, Ashmore J, Morris HP, et al. Comparative biochemistry of hepatomas: part 6. Isotope studies of glucose and fructose metabolism in liver tumors of different growth rate. Cancer Res. 1963;23:995-1002.
31. Kubota R, Kubota K, Yamada S, et al. Active and passive mechanisms of [fluorine-18] fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiographic study. J Nucl Med. 1994;35:1067-1075.
32. Shields AF, David AM, Jeanne ML, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med. 1998;39:1757-1762.
33. Shields AF. Measurement of tumor proliferation using [C-11] thymidine and PET. In: Matszawa T, ed. Proceedings of the Second International Symposium of Clinical PET in Oncology. Singapore, Singapore: World Scientific; 1994:41-45.
34. Dunnill MS, Gatter KC. Cellular heterogeneity in lung cancer. Histopathology. 1986;10:461-475.
35. Carey FA, Fabbronni G, Lamb D. Expression of proliferating cell nuclear antigen in lung cancer: a systematic study and correlation with DNA ploidy. Histopathology. 1992;20:499-503.
36. Keyes JW. SUV; standard uptake or silly useless value? J Nucl Med. 1995;36:1836-1839.
37. 68Ge transmission scan in PET study. Kaku Igaku. 1994;31:1511-1517.
38. Ogawa J, Tsurumi T, Yamada S, Koide S, Shohtsu A. Blood vessel invasion and expression of sialyl lewis and proliferating cell nuclear antigen in stage I non-small cell lung cancer. Cancer. 1994;73:1177-1183.
39. Ishida T, Kaneko S, Akazawa k, Tateishi M, Sugimachi K. Proliferating cell nuclear antigen expression and argyrophilic nuclear organizer regions as factors influencing prognosis of surgically treated lung cancer patients. Cancer Res. 1993;53:5000-5003.